Neuro Medtech Investors Have Time (And Money) For The Pain
This article was originally published in Start Up
START-UP reviews five years of fundraising and exit activities for privately held medtech and diagnostics companies developing neurology treatments. Part 2 of our series on neuro-focused capital raising and bow-outs.
You may also be interested in...
August was another slow month for announcements of medical device approvals outside the US, but the short list of non-US approvals this month includes a broad range of device-types approved, notably a much-awaited expanded indication for Medtronic’s CoreValve Evolut R, in six different territories.
The neuromodulation market is growing at a rapid pace and investors and strategics are paying close attention to early-stage innovators. We highlight Cardionomic, Nuviant and Pixium, three young companies that are listening to the brain, fixing broken hearts and making the blind see.
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.